Grivas, P., Valderrama, B. P., Tsiatas, M., Chang, P. M., Kim, M., Antonuzzo, L., Shin, S. J., Gakis, G., Blais, N., Kim, S. H., Arija, J. Ã. A., Su, H. Y., Zagouri, F., Maruzzo, M., Schneider, A., Tyroller, K., Hoffman, J., Jacob, N., Hoffman-Censits, J. (2026). Avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Updated subgroup analyses of JAVELIN Bladder Medley based on metastatic sites.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4568